{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:12Z","timestamp":1789646592372,"version":"4.0.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:00:00Z","timestamp":1423785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,4]]},"abstract":"\n Aims<\/jats:title>\n \n To report baseline characteristics and cardiovascular (\n CV<\/jats:styled-content>\n ) risk management by region, age, sex and\n CV<\/jats:styled-content>\n event type for 14\u2009724 participants in the\n T<\/jats:styled-content>\n rial\n E<\/jats:styled-content>\n valuating\n C<\/jats:styled-content>\n ardiovascular\n O<\/jats:styled-content>\n utcomes with\n S<\/jats:styled-content>\n itagliptin (\n TECOS<\/jats:styled-content>\n ), a randomized, double\u2010blind, placebo\u2010controlled trial exploring whether sitagliptin added to usual type 2 diabetes (\n T2DM<\/jats:styled-content>\n ) care affects time to first event in the composite endpoint of\n CV<\/jats:styled-content>\n death, non\u2010fatal myocardial infarction (\n MI<\/jats:styled-content>\n ), non\u2010fatal stroke or unstable angina hospitalization.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n TECOS<\/jats:styled-content>\n enrolled patients aged \u226550\u2009years, with\n T2DM<\/jats:styled-content>\n and\n CV<\/jats:styled-content>\n disease from 38 countries in five regions:\n N<\/jats:styled-content>\n orth\n A<\/jats:styled-content>\n merica,\n E<\/jats:styled-content>\n astern\n E<\/jats:styled-content>\n urope,\n W<\/jats:styled-content>\n estern\n E<\/jats:styled-content>\n urope,\n A<\/jats:styled-content>\n sia\n P<\/jats:styled-content>\n acific and\n L<\/jats:styled-content>\n atin\n A<\/jats:styled-content>\n merica. Participants had a glycated haemoglobin concentration of 6.5\u20138.0% (48\u201364\u2009mmol\/mol) and were receiving oral and\/or insulin\u2010based antihyperglycaemic therapy. Analysis of variance or logistic regression was used to compare regional\n CV<\/jats:styled-content>\n risk factors and treatments, referenced to\n N<\/jats:styled-content>\n orth\n A<\/jats:styled-content>\n merica.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients had a mean [1 standard deviation (SD)] age of 66 (8)\u2009years, a median (interquartile range) diabetes duration of 9.4 (4.9, 15.3)\u2009years, and a mean (SD) body mass index 30.2 (5.7)\u2009kg\/m\n 2<\/jats:sup>\n . Compared with\n N<\/jats:styled-content>\n orth\n A<\/jats:styled-content>\n merica, blood pressure and lipids were higher in all regions. Statin use was lowest in\n L<\/jats:styled-content>\n atin\n A<\/jats:styled-content>\n merica (68%) and\n E<\/jats:styled-content>\n astern\n E<\/jats:styled-content>\n urope (70%) and aspirin use was lower compared with\n N<\/jats:styled-content>\n orth\n A<\/jats:styled-content>\n merica in all regions except\n A<\/jats:styled-content>\n sia\n P<\/jats:styled-content>\n acific. Achievement of treatment targets did not differ by age group or insulin usage, but men and participants with previous\n MI<\/jats:styled-content>\n were more likely than women or those with previous stroke or peripheral arterial disease to reach most treatment goals.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The\n CV<\/jats:styled-content>\n risk factors of participants in\n TECOS<\/jats:styled-content>\n are reasonably controlled, but differences in\n CV<\/jats:styled-content>\n risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12441","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T04:09:14Z","timestamp":1421726954000},"page":"395-402","source":"Crossref","is-referenced-by-count":34,"title":["Regional, age and sex differences in baseline characteristics of patients enrolled in the\n T<\/scp>\n rial\n E<\/scp>\n valuating\n C<\/scp>\n ardiovascular\n O<\/scp>\n utcomes with\n S<\/scp>\n itagliptin (\n TECOS<\/scp>\n )"],"prefix":"10.1111","volume":"17","author":[{"given":"M. A.","family":"Bethel","sequence":"first","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Green","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Milton","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tajar","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Engel","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories Merck Sharp & Dohme Corp. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Califf","sequence":"additional","affiliation":[{"name":"Duke Translational Medicine Institute Duke University Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TECOS Executive Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000154568.43333.82"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61215-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.09.003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2011.04.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2014.04.1106"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-15-123"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.18.2480"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318287cf2f"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31820faaf8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa053935"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182009701"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-544"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000112"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12415"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21969"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02402.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.12.3333"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht108"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-S055"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm124"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12441","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:47Z","timestamp":1761886667000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,13]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/dom.12441"],"URL":"https:\/\/doi.org\/10.1111\/dom.12441","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,13]]}}}